Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 284 results for alcohol

  1. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  2. Hand decontamination:- When clean running water is not available, what is the clinical and cost effectiveness of using wipes, gels, handrubs or other products to remove visible contamination?

    determined. A randomised controlled trial is required to compare hand wipes (alcohol and antiseptic), hand gels and other hand...

  3. Alcohol dependence: nalmefene (ESNM29)

    This evidence summary has been replaced by NICE technology appraisal guidance 325.

  4. Extended access to social care services:- What is the clinical and cost effectiveness of providing extended access to social care services, for example during early mornings and evenings, and 7 days a week?

    practical assistance because of their age, illness, disability, dependence on alcohol or drugs, or any other similar circumstances. This...

  5. Hypertension in adults. Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of medicines

    active. : Trying to get to a healthier weight. : Avoiding drinking too much alcohol. : Stopping smoking. : You'll take medicines to...

  6. Alcohol: school-based interventions (PH7)

    This guideline has been updated and replaced by NICE guideline NG135.

  7. Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

    This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  8. ORA G3 to measure corneal hysteresis (MIB150)

    NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis .

  9. Post-traumatic stress disorder (NG116)

    This guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD such as anxiety, sleep problems and difficulties with concentration. Recommendations also aim to raise awareness of the condition and improve coordination of care.

  10. Spinal injury: assessment and initial management (NG41)

    This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It covers traumatic injuries to the spine but does not cover spinal injury caused by a disease. It aims to reduce death and disability by improving the quality of emergency and urgent care.

  11. The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)

    NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy

  12. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

  13. Parkinson's disease in adults (NG71)

    This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.

  14. Is the application of antiseptics and antibiotics in the operative field before wound closure, clinically and cost effective in reducing surgical site infection rates?

    This evidence also suggested that topical antiseptics, such as iodine in alcohol solution, are not effective in reducing surgical site...

  15. Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

    Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.